EODData

MEMBERSHIP REGISTER LOG IN

LSE, 0RD1: Camurus AB

11 Nov 2025
LAST:

615.0

CHANGE:
 12.02		OPEN:
615.5		HIGH:
619.0		ASK:
0.0		VOLUME:
37.0K
CHG(%):
1.92		PREV:
627.0		LOW:
605.0		BID:
0.0		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
11 Nov 25615.5619.0605.0615.037.0K
10 Nov 25611.0630.0602.0627.015.3K
07 Nov 25552.5558.0543.0552.116.9K
06 Nov 25542.0570.0542.0552.311.6K
05 Nov 25609.0609.0591.0593.57.2K
04 Nov 25624.3624.3609.0612.812.6K
03 Nov 25634.5637.0627.5633.15.1K
31 Oct 25630.8630.8626.0627.3302
30 Oct 25614.0624.5613.5618.42.2K
29 Oct 25619.5623.0617.0620.02.8K

COMPANY PROFILE

Name:Camurus AB
About:Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain; and Brixadi to treat opioid use disorder. It also provides CAM2038 for the treatment of chronic pain; CAM2029, which completed phase III clinical trials for the treatment of acromegaly, and phase III clinical trials to treat gastroenteropancreatic neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud's phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM2056 that is in phase I clinical trials for the treatment of metabolic diseases; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; and CAM2047 that is in phase 1 clinical trial for the treatment of chemotherapy-induced nausea and vomiting. It has strategic partnerships with Braeburn Pharmaceuticals to develop CAM2038 for the treatment of opioid use disorder; and Rhythm Pharmaceuticals Inc. to develop CAM4072 for the treatment of a range of rare genetic disorders of obesity, as well as NewBridge Pharmaceuticals. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.
Address:Ideon Science Park, Lund, Sweden, 223 70
Website:https://www.camurus.com
ISIN:SE0007692850
LEI:5493003S6Z6VI7WYFQ06

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

TECHNICAL INDICATORS

MA5:587.974.6%
MA10:605.131.6%
MA20:626.801.9%
MA50:668.988.8%
MA100:670.259.0%
MA200:632.732.9%
STO9:74.08
STO14:61.13
RSI14:40.45
WPR14:-35.09
MTM14:-34.02
ROC14:-0.05 
ATR:22.70 
Week High:630.002.4%
Week Low:542.0013.5%
Month High:697.5013.4%
Month Low:542.002.9%
Year High:749.0021.8%
Year Low:496.8023.8%
Volatility:1.88 

RECENT SPLITS

Date Ratio
06 Mar 20191113-1019

RECENT DIVIDENDS

Date Amount
01 Sep 2022$0.90